Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M198,877Revenue (TTM) $M41,729Net Margin (%)8.0Altman Z-Score3.9
Enterprise Value $M212,418EPS (TTM) $1.3Operating Margin %20.7Piotroski F-Score8
P/E(ttm)61.2Beneish M-Score-3.0Pre-tax Margin (%)19.1Higher ROA y-yY
Price/Book6.310-y EBITDA Growth Rate %-0.2Quick Ratio1.2Cash flow > EarningsY
Price/Sales5.05-y EBITDA Growth Rate %-5.9Current Ratio1.4Lower Leverage y-yY
Price/Free Cash Flow23.1y-y EBITDA Growth Rate %55.7ROA % (ttm)3.8Higher Current Ratio y-yY
Dividend Yield %2.6PEG--ROE % (ttm)9.8Less Shares Outstanding y-yY
Payout Ratio %154Shares Outstanding M2,600ROIC % (ttm)7.3Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

MRK is held by these investors:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History

MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PERLMUTTER ROGER MExe V-P & Pres, MRL 2018-11-08Sell225,443$75.271.61view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2018-11-07Sell36,218$75.141.78view
Schechter Adam HEVP & Pres-Global Human Health 2018-11-01Sell277,879$73.813.62view
Watson AshleySVP Chief Ethics & Com Officer 2018-10-31Sell47,036$74.332.89view
DeLuca Richard R.EVP&Pres, Merck Animal Health 2018-10-30Sell25,467$726.22view
FRAZIER KENNETH CChairman, President & CEO 2018-10-02Sell279,850$72.076.12view
FRAZIER KENNETH CChairman, President & CEO 2018-09-18Sell279,851$70.089.13view
Schechter Adam HEVP & Pres-Global Human Health 2018-09-17Sell107,360$70.188.98view
Chattopadhyay SanatExe V-P & Pres. MMD 2018-08-03Sell29,208$65.217.3view
Karachun Rita ASr. VP Fince-Global Controller 2018-08-02Sell5,000$65.0117.64view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

News about MRK:

Articles On GuruFocus.com
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy Dec 10 2018 
Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Exp Dec 06 2018 
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refracto Nov 19 2018 
Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets Oct 10 2018 
Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Poten Oct 09 2018 
New Efficacy and Safety Data on MS Portfolio to Be Presented at ECTRIMS 2018 Oct 08 2018 
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in P Sep 11 2018 
Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M782 Jun 04 2018 
Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO Jun 04 2018 
Merck KGaA, Darmstadt, Germany Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018 Jun 03 2018 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat